WallStreetZenWallStreetZen

NYSE: ABT
Abbott Laboratories Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ABT past earnings growth

How has ABT's earnings growth performed historically?
Company
-16.75%
Industry
87.87%
Market
107.64%
ABT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ABT's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ABT's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ABT past revenue growth

How has ABT's revenue growth performed historically?
Company
-8.12%
Industry
9.39%
Market
17.61%
ABT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ABT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ABT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ABT earnings and revenue history

Current Revenue
$40.1B
Current Earnings
$5.7B
Current Profit Margin
14.3%
ABT's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

ABT Return on Equity

Current Company
15.1%
Current Industry
10.5%
Current Market
188%
ABT's Return on Equity (15.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ABT announces earnings.

ABT Return on Assets

Current Company
7.8%
Current Industry
5.3%
ABT is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ABT Return on Capital Employed

Current Company
12.3%
Current Industry
8.3%
ABT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABT vs Medical Device Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ABT$40.11B$10.54B$5.72B+5.58%+19.61%
SYK$20.50B$4.07B$3.17B+8.55%-2.57%
MDT$32.32B$8.88B$4.20B+1.13%-2.90%
BSX$14.24B$3.45B$1.57B+7.71%-2.25%
EW$6.00B$1.79B$1.40B+10.03%+14.97%
View Top Medical Device Stocks

Abbott Laboratories Earnings & Revenue FAQ

What were ABT's earnings last quarter?

On Invalid Date, Abbott Laboratories (NYSE: ABT) reported Q4 2023 earnings per share (EPS) of $0.92, up 55.93% year over year. Total Abbott Laboratories earnings for the quarter were $1.59 billion. In the same quarter last year, Abbott Laboratories's earnings per share (EPS) was $0.59.

If you're new to stock investing, here's how to buy Abbott Laboratories stock.

What was ABT's earnings growth in the past year?

As of Q2 2024, Abbott Laboratories's earnings has grown -16.75% year over year. This is 104.62 percentage points lower than the US Medical Devices industry earnings growth rate of 87.87%. Abbott Laboratories's earnings in the past year totalled $5.72 billion.

What was ABT's revenue last quarter?

On Invalid Date, Abbott Laboratories (NYSE: ABT) reported Q4 2023 revenue of $10.24 billion up 1.49% year over year. In the same quarter last year, Abbott Laboratories's revenue was $10.09 billion.

What was ABT's revenue growth in the past year?

As of Q2 2024, Abbott Laboratories's revenue has grown -8.12% year over year. This is 17.51 percentage points lower than the US Medical Devices industry revenue growth rate of 9.39%. Abbott Laboratories's revenue in the past year totalled $40.11 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.